Consensus Report on Truncal Acne: The Korean Acne and Rosacea Society Experts Panel
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: More than half of acne patients have truncal acne on their chest, back, and shoulders. However, since most studies on acne have focused on the face, data on clinical characteristics and proper management for truncal acne are insufficient. Objective: To establish a Korean Acne Rosacea Society (KARS) consensus for experts’ perception and treatment patterns of truncal acne. Methods: We conducted two rounds of the Dephi technique to gather expert opinion and reach a consensus on truncal acne. The first round comprised 48 questionnaires focusing on various aspects such as epidemiology, clinical features, diagnosis, treatment, prognosis and more, while second rounds consisted of 26 questionnaires. Results: A total of 36 dermatologists (36/38 KARS members, 94.7%) completed this sur vey. In the first-round sur vey, consensus was reached on 20 out of the 48 questions (41.7%). In the second- round questionnaire, consensus was achieved on 9 of the 26 questions (34.6%). The most unresponsive lesion to truncal acne treatment was scars (atrophic/hypertrophic). The most commonly used treatments for each non-inflammator y and inflammator y truncal acne lesions were selected to use topical retinoids (78.1% of the responders) and oral antibiotics (93.8% of the responders). Conclusion: Our study has yielded valuable insights into the epidemiology, clinical manifestations, diagnosis, treatment, and quality of life of patients with truncal acne. We anticipate that this study will inspire further comprehensive research for individuals with truncal acne.
Abstract
Background: More than half of acne patients have truncal acne on their chest, back, and shoulders. However, since most studies on acne have focused on the face, data on clinical characteristics and proper management for truncal acne are insufficient. Objective: To establish a Korean Acne Rosacea Society (KARS) consensus for experts’ perception and treatment patterns of truncal acne. Methods: We conducted two rounds of the Dephi technique to gather expert opinion and reach a consensus on truncal acne. The first round comprised 48 questionnaires focusing on various aspects such as epidemiology, clinical features, diagnosis, treatment, prognosis and more, while second rounds consisted of 26 questionnaires. Results: A total of 36 dermatologists (36/38 KARS members, 94.7%) completed this sur vey. In the first-round sur vey, consensus was reached on 20 out of the 48 questions (41.7%). In the second- round questionnaire, consensus was achieved on 9 of the 26 questions (34.6%). The most unresponsive lesion to truncal acne treatment was scars (atrophic/hypertrophic). The most commonly used treatments for each non-inflammator y and inflammator y truncal acne lesions were selected to use topical retinoids (78.1% of the responders) and oral antibiotics (93.8% of the responders). Conclusion: Our study has yielded valuable insights into the epidemiology, clinical manifestations, diagnosis, treatment, and quality of life of patients with truncal acne. We anticipate that this study will inspire further comprehensive research for individuals with truncal acne.
참고문헌 (41)
- Smithard A, "Acne prevalence, knowledge about acne and psychological morbidity in mid-adolescence: a community-based study", Br J Dermatol, 145, pp.274~279 (2001)
- Del Rosso JQ, "A closer look at truncal acne vulgaris : prevalence, severity, and clinical significance", J Drugs Dermatol, 6, pp.597~600 (2007)
- Del Rosso JQ, "Truncal acne : a neglected entity", J Drugs Dermatol, 18, pp.205~1208 (2019)
- Bell KA, "Trifarotene for the treatment of facial and truncal acne", Ann Pharmacother, 55, pp.111~116 (2021)
- Kim BR, "Sebum secretion of the trunk and the development of truncal acne in women : do truncal acne and sebum affect each other?", Dermatology, 231, pp.87~93 (2015)
- Poli F, "Truncal acne, what do we know?", J Eur Acad Dermatol Venereol, 34, pp.2241~2246 (2020)
- Tan J, "Gaps and recommendations for clinical management of truncal acne from the personalising acne : consensus of experts panel", JAAD Int, 5, pp.33~40 (2021)
- Leyden JJ, "Efficacy of benzoyl peroxide (5.3%) emollient foam and benzoyl peroxide (8%) wash in reducing Propionibacterium acnes on the back", J Drugs Dermatol, 9, pp.622~625 (2010)
- Palli MB, "A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone", 0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris, 2013, pp.12, 633~637
- Leyden JJ, "The effect of benzoyl peroxide 9. 8% emollient foam on reduction of Propionibacterium acnes on the back using a short contact therapy approach", J Drugs Dermatol, 11, pp.830~833 (2012)
- Del Rosso JQ, "Management of truncal acne vulgaris with topical dapsone 7.5% gel", J Clin Aesthet Dermatol, 11, pp.45~50 (2018)
- Hoffman LK, "The efficacy and safety of azelaic acid 15% foam in the treatment of truncal acne vulgaris", J Drugs Dermatol, 16, pp.534~538 (2017)
- Cunliffe WJ, "Evolution of a strategy for the treatment of acne", J Am Acad Dermatol, 16, pp.591~599 (1987)
- Ganceviciene R, "Isotretinoin: state of the art treatment for acne vulgaris", J Dtsch Dermatol Ges, 8(Suppl 1), pp.S47~S59 (2010)
- Layton A, "The use of isotretinoin in acne", Dermatoendocrinol, 1, pp.162~169 (2009)
- Bikowski JB, "Subantimicrobial dose doxycycline for acne and rosacea", Skinmed, 2, pp.234~245 (2003)
- Skidmore R, "Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne", Arch Dermatol, 139, pp.459~464 (2003)
- Garner SE, "Minocycline for acne vulgaris : efficacy and safety", Cochrane Database Syst Rev, 2012, pp.CD002086~ (2012)
- Ochsendorf F, "Minocycline in acne vulgaris : benefits and risks", Am J Clin Dermatol, 11, pp.327~341 (2010)
- Charny JW, "Spironolactone for the treatment of acne in women, a retrospective study of 110 patients", Int J Womens Dermatol, 3, pp.111~115 (2017)
- Muhlemann MF, "Oral spironolactone : an effective treatment for acne vulgaris in women", Br J Dermatol, 115, pp.227~232 (1986)
- Eastman WJ, "Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis", Cutis, 94, pp.46~53 (2014)
- Turegano M, "Cosmeceuticals for acne and rosacea" (2021), Karg¬er Publishers
- Amer SS, "Cosm-nutraceutical nanovesicles for acne treatment : physicochemical characterization and exploratory clinical experimentation", Int J Pharm, 577, pp.119092~ (2020)
- Kim S, "Treatment of facial postinflammatory hyperpigmentation with facial acne in Asian patients using a Q-switched neodymium-doped yttrium aluminum garnet laser", Dermatol Surg, 36, pp.1374~1380 (2010)
- Panchaprateep R, "Low-fluence 585 nm Q-switched Nd : YAG laser : a novel laser treatment for post-acne erythema", Lasers Surg Med, 47, pp.148~155 (2015)
- Zawar VP, "Treatment of postinflammatory pigmentation due to acne with Q-switched neodymium-doped yttrium aluminum garnet in 78 Indian cases", J Cutan Aesthet Surg, 8, pp.222~226 (2015)
- Moftah NH, "Intense pulsed light versus photodynamic therapy using liposomal methylene blue gel for the treatment of truncal acne vulgaris : a comparative randomized split body study", Arch Dermatol Res, 308, pp.263~268 (2016)
- Taylor M, "Intense pulsed light may improve inflammatory acne through TNF-α down-regulation", J Cosmet Laser Ther, 16, pp.96~103 (2014)
- Thiboutot DM, "Practical management of acne for clinicians : an international con¬sensus from the global alliance to improve outcomes in acne", J Am Acad Dermatol, 78, pp.S1~S23 (2018)
- Abdel Hay R, "Interventions for acne scars", Cochrane Database Syst Rev, 4, pp.CD011946~ (2016)
- Rivera AE, "Acne scarring : a review and current treatment modalities", J Am Acad Dermatol, 59, pp.659~676 (2008)
- St Surin-Lord S, "Topical treatment of truncal acne with treti¬noin lotion 0. 05% and azelaic acid foam", Case Rep Dermatol Med, 2020, pp.5217567~ (2020)
- Blume-Peytavi U, "Long-term safety and efficacy of trifarotene 50 μg", g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne, 2020, pp.34, 166~173
- Wagner N, "Clinical pharmacology and safety of trifarotene, a first-in-class rarγ-selective topical retinoid", J Clin Pharmacol, 60, pp.660~668 (2020)
- Tan J, "Impact of facial and truncal acne on quality of life : a multi-country population-based survey", JAAD Int, 3, pp.102~110 (2021)
- Agnew T, "A comprehensive critique and review of published measures of acne severity", J Clin Aesthet Dermatol, 9, pp.40~52 (2016)
- Bernardis E, "Development and initial validation of a multidimensional acne global grading system integrating primary lesions and secondary changes", JAMA Dermatol, 156, pp.296~302 (2020)
- Layton AM, "The Personalized Acne Treatment Tool-Recommendations to facilitate a patient-centered approach to acne management from the Personalizing Acne : Consensus of Experts", JAAD Int, 12, pp.60~69 (2023)
- Thomas CL, "Objective severity does not capture the impact of rosacea, acne scarring and photoaging in patients seeking laser therapy", J Eur Acad Dermatol Venereol, 31, pp.361~366 (2017)
- Hayashi N, "A cross-sectional analysis of quality of life in Japanese acne patients using the Japanese version of Skindex-16", J Dermatol, 31, pp.971~976 (2004)